<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895488</url>
  </required_header>
  <id_info>
    <org_study_id>CAVES</org_study_id>
    <secondary_id>2021-001333-38</secondary_id>
    <nct_id>NCT04895488</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia</brief_title>
  <acronym>CAVES</acronym>
  <official_title>Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to assess the efficacy of Vortioxetine compared with treatment as usual in&#xD;
      early schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial to assess the efficacy of Vortioxetine, compared with treatment as usual in&#xD;
      early schizophrenia. Propose: To investigate the effect of Vortioxetine in cognitive&#xD;
      functioning and negative symptoms severity in early schizophrenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A two arm, Open-label, randomized, Cross-over Design and single-center clinical trial Phase II b /Phase III.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open Label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effectiveness of Vortioxetine vs. TAU measured by the change in Brief Assessment of Cognition in Schizophrenia (BACS App) scores</measure>
    <time_frame>Baseline, week 24, week 26 and week 50</time_frame>
    <description>To assess the effectiveness of Vortioxetine vs. TAU in the treatment of cognitive impairments in early psychosis, measured by the change From Baseline to Week 24 in BACS App scores using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effectiveness of Vortioxetine vs. TAU measured by the change in Negative Symptoms severity (Scale for Assessment of Negative Symptoms (SANS) and Negative Symptom Assessment-4 (NSA-4) total scores)</measure>
    <time_frame>Baseline, week 4, week 12, week 24, week 26, week 30, week 38 and week 50</time_frame>
    <description>To assess the effectiveness of Vortioxetine vs. TAU in the treatment of negative symptoms in early psychosis, measured by the change in Negative Symptoms severity (SANS, NSA-4 total scores) from baseline to end of trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the effectiveness of Vortioxetine vs. TAU measured by the change in general functioning</measure>
    <time_frame>baseline, week 12, week 24, week 26, week 38 and week 50</time_frame>
    <description>To assess the effectiveness of Vortioxetine vs. TAU in the treatment of cognitive impairments in early psychosis, measured by the change in general functioning (Global Assessment of Functioning (GAF) total score)</description>
  </other_outcome>
  <other_outcome>
    <measure>To assess the safety of Vortioxetine measured through the communication of any serious adverse event.</measure>
    <time_frame>from informed consent form (ICF) signature to 52 weeks</time_frame>
    <description>To assess the safety of Vortioxetine in patients with early psychosis measured through the communication of any serious adverse event evaluated for relationship with the Investigational Medicinal Product (IMP).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Cognitive Impairment With Primary Psychotic Disorder</condition>
  <condition>Negative Symptoms With Primary Psychotic Disorder</condition>
  <arm_group>
    <arm_group_label>Arm A: Vortioxetine+Usual antipsychotic treatment (TAU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:&#xD;
First treatment phase: Vortioxetine 10 mg 1 tablet/d for 2 weeks added to Usual antipsychotic treatment, followed by Vortioxetine 20mg 1tablet/d for 22 weeks added to Usual antipsychotic treatment.&#xD;
Wash-out period 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Usual antipsychotic treatment (TAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second treatment phase: Usual antipsychotic treatment: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.&#xD;
Wash-out period 2 weeks</description>
    <arm_group_label>Arm A: Vortioxetine+Usual antipsychotic treatment (TAU)</arm_group_label>
    <arm_group_label>Arm B: Usual antipsychotic treatment (TAU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Antipsychotic Treatment</intervention_name>
    <description>Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.</description>
    <arm_group_label>Arm A: Vortioxetine+Usual antipsychotic treatment (TAU)</arm_group_label>
    <arm_group_label>Arm B: Usual antipsychotic treatment (TAU)</arm_group_label>
    <other_name>TAU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient&#xD;
&#xD;
          2. Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental&#xD;
             Disorders (DSM - SCID) diagnosis of Schizophrenia spectrum disorders.&#xD;
&#xD;
          3. Age &gt;18-50 years old&#xD;
&#xD;
          4. Stable antipsychotic medication doses during at least 4 weeks ( all second generation&#xD;
             antipsychotics excluding clozapine).&#xD;
&#xD;
          5. No antidepressant treatment for at least 8 weeks prior to randomization.&#xD;
&#xD;
          6. PANSS Negative subscore &gt;14 with at least two of the items at a level &gt;/=4 (moderate)&#xD;
&#xD;
          7. PANSS Positive subscore &lt;/=14 with not more than one of the items at a level &gt;/=4&#xD;
             (moderate)&#xD;
&#xD;
          8. Hamilton Depression Rating Scale (HAMD-17) total score &lt;/=12&#xD;
&#xD;
          9. Simpson Angus Score of any item &lt;2&#xD;
&#xD;
         10. Behaviorally Anchored Rating Scale (BARS) of any item &lt;/= 1&#xD;
&#xD;
         11. Competent and willing to sign informed consent&#xD;
&#xD;
         12. The patient, if a woman, must: agree not to try to become pregnant during the study&#xD;
             and use adequate, highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients taking any antidepressant and its use cannot be discontinued at least 8 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          2. Structural brain disease (based on previous medical records)&#xD;
&#xD;
          3. Cognitive disability by history and estimated intelligence quotient (IQ) &lt;70 (ID DSM-5&#xD;
             diagnosis).&#xD;
&#xD;
          4. Any serious chronic medical illnesses that may interfere with the patient's ability to&#xD;
             comply with the study procedures or that will interfere with cognition.&#xD;
&#xD;
          5. Organic mental disorders, or mental disorders due to a general medical condition. Any&#xD;
             neurological or neurodegenerative disorders.&#xD;
&#xD;
          6. Any current diagnosis of substance abuse or dependence.&#xD;
&#xD;
          7. Serious risk of suicide.&#xD;
&#xD;
          8. Patients with thyroid conditions.&#xD;
&#xD;
          9. Intolerance to or inefficacy of vortioxetine in the past. Patients who had failed&#xD;
             treatment with vortioxetine were also excluded.&#xD;
&#xD;
         10. Pregnant or breastfeeding female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedicto Crespo Facorro, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>benedicto.crespo.sspa@juntadeandalucia.es</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara M. Rosso Fernández, PhD</last_name>
    <phone>+34 955 013414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Benedicto Crespo Facorro, Professor</last_name>
      <phone>+34671596675</phone>
      <email>benedicto.crespo.sspa@juntadeandalucia.es</email>
    </contact>
    <contact_backup>
      <last_name>Idalino Rocha, MSc</last_name>
      <phone>+34689366067</phone>
      <email>idalino.rocha@juntadeandalucia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Benedicto Crespo Facorro, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Ruiz Veguilla, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

